SCHEMBL1355725

SCHEMBL1355725

COc1ccc(-n2ncc3cnc(Nc4ccc(CCO)cc4)nc32)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EIF2AK4 Q9P2K8 4/20 0.64
KDR P35968 3/20 0.55
CDK1 P06493 2/20 0.55
TBK1 Q9UHD2 2/20 0.51
CDK4 P11802 1/20 0.47
CCND1 P24385 1/20 0.47
CCND2 P30279 1/20 0.47
CCND3 P30281 1/20 0.47
FLT3 P36888 5/20 0.45
ABL1 P00519 2/20 0.44
PDGFRB P09619 2/20 0.44
PDGFRA P16234 2/20 0.44
MAPK14 Q16539 2/20 0.44
SRC P12931 1/20 0.44
EGFR P00533 1/20 0.44
MAPT P10636 2/20 0.43
LMNA P02545 1/20 0.43
TP53 P04637 1/20 0.43
MAPK9 P45984 3/20 0.43
MAPK8 P45983 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1356007 0.86 EIF2AK4 (0.67) EIF2AK4KDRTBK1CDK4CCND1
SCHEMBL1356186 0.84 EIF2AK4 (0.67) EIF2AK4KDRTBK1CDK4CCND1
SCHEMBL1353786 0.82 EIF2AK4 (0.62) EIF2AK4TBK1CDK4CCND1CCND2
SCHEMBL1355646 0.82 FLT3 (0.64) EIF2AK4TBK1CDK4CCND1CCND2
SCHEMBL1356855 0.82 EIF2AK4 (0.64) EIF2AK4KDRTBK1CDK4CCND1
SCHEMBL1355069 0.81 EIF2AK4 (0.61) EIF2AK4TBK1CDK4CCND1CCND2
SCHEMBL1355573 0.81 EIF2AK4 (0.61) EIF2AK4KDRTBK1CDK4CCND1
SCHEMBL1355825 0.81 EIF2AK4 (0.60) EIF2AK4TBK1CDK4CCND1CCND2
SCHEMBL1356787 0.80 EIF2AK4 (0.60) EIF2AK4TBK1FLT3EGFRMAPT
SCHEMBL1355752 0.80 EIF2AK4 (0.62) EIF2AK4KDRCDK1TBK1CDK4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US claimed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US claimed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP claimed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO claimed
US-20110281821-A9 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2011-11-17 US disclosed
US-20100249067-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC. (US) 2010-09-30 US disclosed
EP-2108020-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP disclosed
WO-2008094602-A2 1-H-PYRAZOLO (3,4B) PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249067-A1 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 EIF2AK4 791/4885KDR 2714/4885CDK1 3/4885
US-20110281821-A9 Modulators of Mitotic Kinases BUB1, BUB1B, CDK1 EIF2AK4 791/4885KDR 2714/4885CDK1 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.